Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 8/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.75 |
| ▸ | TSHR | P16473 | 3/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.69 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484957 | 0.94 | CYP3A4 (0.68) | CYP2C9CYP3A4TSHRCYP2C19HIF1A | |
| SCHEMBL640636 | 0.91 | ITGB3 (0.67) | CYP2C9CYP3A4TSHRCYP2C19HIF1A | |
| SCHEMBL484916 | 0.91 | ITGB3 (0.68) | CYP2C9CYP3A4TSHRCYP2C19HIF1A | |
| SCHEMBL16611629 | 0.89 | CYP2C9 (0.64) | CYP2C9CYP3A4TSHRCYP2C19HIF1A | |
| SCHEMBL639215 | 0.86 | CYP3A4 (0.68) | CYP2C9CYP3A4TSHRCYP2C19HIF1A | |
| SCHEMBL3096735 | 0.86 | CYP2C9 (1.00) | CYP2C9CYP3A4TSHRCYP2C19HIF1A | |
| SCHEMBL3404750 | 0.84 | SMN1; SMN2 (0.57) | CYP2C9CYP3A4TSHRCYP2C19HIF1A | |
| SCHEMBL2819013 | 0.84 | MEN1 (0.78) | CYP2C9CYP3A4TSHRCYP2C19HIF1A | |
| SCHEMBL21855140 | 0.81 | USP2 (0.56) | CYP2C9CYP3A4TSHRCYP2C19HIF1A | |
| SCHEMBL7018518 | 0.81 | ITGB3 (1.00) | CYP2C9CYP3A4TSHRCYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2857388-A1 | Azoles containing sulfone | Grünenthal GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| EP-2393812-B1 | SUBSTITUTED SPIROAMIDES AS B1R-MODULATORS | GRUENENTHAL GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| EP-2440542-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-8119805-B2 | Substituted disulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2393803-A1 | SUBSTITUTED INDOLE COMPOUNDS AS BRADYKININ RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2350003-A1 | SUBSTITUTED DISULFONAMIDES AS BRI-MODULATORS | Grünenthal GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010142402-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2010-12-16 | — | — | WO | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010089084-A1 | SUBSTITUTED INDOLE COMPOUNDS AS BRADYKININ RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2010-08-12 | — | — | WO | disclosed |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| WO-2010051977-A1 | SUBSTITUTED DISULFONAMIDES AS BRI-MODULATORS | Grünenthal GmbH (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152158-A1 | Substituted Disulfonamide Compounds | BDKRB1, BDKRB2, BRS3 | CYP2C9 671/4885CYP3A4 2223/4885TSHR 287/4885 |
| US-20100234340-A1 | Substituted Spiroamide Compounds | BDKRB1, BDKRB2, AVPR1B | CYP2C9 351/4885CYP3A4 1215/4885TSHR 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.